Discover 3,005 paid clinical trials in Riverside, California. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Filter
2
Filter results
Results: 3,005
Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial
for
Castration-Resistant Prostate Carcinoma,
Location: Orange CA, Irvine CA, Encinitas CA, La Jolla CA,
Sponsor: Alliance for Clinical Trials in Oncology
Sex: All
Age: 18+
Code: NCT06632977
Phase 2, Recruiting
Testing the Addition of Anti-cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment, Cetuximab Plus Encorafenib, for Colorectal Cancer
for
Metastatic Colorectal Adenocarcinoma,
Location: Orange CA, Irvine CA, Costa Mesa CA, Los Angeles CA,
Sponsor: National Cancer Institute (NCI)
Sex: All
Age: 18+
Code: NCT06102902
Phase 1, Recruiting
A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan-hziy Versus Standard of Care in the Treatment of Advanced Urothelial Cancer
for
Locally Advanced Urothelial Carcinoma,
Location: Orange CA, Irvine CA, Phoenix AZ, Anaconda MT,
Sponsor: National Cancer Institute (NCI)
Sex: All
Age: 18+
Code: NCT06524544
Phase 3, Recruiting
Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer
for
Head and Neck Squamous Cell Carcinoma,
Location: Orange CA, Irvine CA, Los Angeles CA, Portland OR,
Sponsor: National Cancer Institute (NCI)
Sex: All
Age: 18+
Code: NCT06980038
Phase 2, Recruiting
Trial to Visualize the Ureters With Nizaracianine Triflutate in Adults Undergoing Abdominopelvic Surgery
for
Injury of Ureter During Surgery (Disorder)
Location: Los Angeles CA, Redwood City CA, Tampa FL, Orlando FL,
Sponsor: Curadel Surgical Innovations, Inc.
Sex: All
Age: 18+
Code: NCT06101745
Phase 2, Phase 3, Recruiting
Interested in new trials?
Get alerts for new trials in your area by subscribing now
Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial
for
Advanced Hepatocellular Carcinoma,
Location: Orange CA, Irvine CA, Sunnyvale CA, Mountain View CA,
Sponsor: NRG Oncology
Sex: All
Age: 18+
Code: NCT07166406
Phase 3, Recruiting
Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC
for
Hepatocellular Carcinoma, Biliary Tract Cancer
Location: Beverly Hills CA, La Jolla CA, Houston TX,
Sponsor: Replimune Inc.
Sex: All
Age: 18+
Code: NCT05733598
Phase 2, Recruiting
CMV CTLs in Neonates With CMV Infection
for
Congenital Cytomegaloviral (CMV) Disease
Location: Los Angeles CA, St Louis MO, Columbus OH, Valhalla NY
Sponsor: New York Medical College
Sex: All
Age: 0
Code: NCT05564598
Phase 2, Recruiting
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study
for
Muscle Invasive Bladder Urothelial Carcinoma,
Location: Orange CA, Irvine CA, La Jolla CA, Sacramento CA,
Sponsor: NRG Oncology
Sex: All
Age: 18+
Code: NCT07097142
Phase 3, Recruiting
Raltegravir and Atazanavir Replacing Current Suppressive Treatment Because of Side Effects in Current Treatment
for
HIV Infections
Location: Los Angeles CA
Sponsor: Peter J. Ruane, M.D., Inc.
Sex: All
Age: 18+
Code: NCT00751153
Recruiting
Post Market Study for VasQ, an External Support Implant for Arteriovenous Fistula
for
End Stage Renal Disease
Location: Long Beach CA, Houston TX, Greenwood MS, Atlanta GA,
Sponsor: Laminate Medical Technologies
Sex: All
Age: 18 - 70+
Code: NCT06516653
Recruiting
Testing the Safety of Anti-Cancer Drug, CX-5461 (Pidnarulex), in Treating Lymphoma With Specific Changes in the MYC Gene
for
Burkitt Lymphoma, Double-Expressor Lymphoma,
Location: Orange CA, Irvine CA, Oklahoma City OK,
Sponsor: National Cancer Institute (NCI)
Sex: All
Age: 18+
Code: NCT07069699
Phase 1, Phase 2, Recruiting
A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma
for
Multiple Myeloma, Secondary Immunodeficiency
Location: Orange CA, Westwood KS, Winnipeg, St Louis MO,
Sponsor: Takeda
Sex: All
Age: 18+
Code: NCT06980480
Phase 3, Recruiting
GPC3-Targeted T-Cell Therapy (ECT204) in Adults With Advanced HCC
Location: Duarte CA, Portland OR, Seattle WA, Dallas TX,
Sponsor: Eureka Therapeutics Inc.
Sex: All
Age: 18+
Code: NCT04864054
Phase 1, Phase 2, Recruiting
Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer
for
Advanced Breast Cancer
Location: Newport Beach CA, Fountain Valley CA, Glendale CA,
Sponsor: AstraZeneca
Sex: All
Age: 18+
Code: NCT06380751
Phase 3, Recruiting
Observational Study Protocol: LIVER-R
for
Hepatobiliary Cancers
Location: Los Angeles CA, Coronado CA, Phoenix AZ,
Sponsor: AstraZeneca
Sex: All
Age: 18 - 70+
Code: NCT06252753
Recruiting
Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With Gastric Cancer Spread to the Abdominal Cavity
for
Gastric Adenocarcinoma,
Location: Orange CA, Irvine CA, Los Angeles CA, Palo Alto CA,
Sponsor: ECOG-ACRIN Cancer Research Group
Sex: All
Age: 18+
Code: NCT07001748
Phase 2, Phase 3, Recruiting
Biliary Atresia Study in Infants and Children
for
Biliary Atresia
Location: Los Angeles CA, Salt Lake City UT, Aurora CO,
Sponsor: Arbor Research Collaborative for Health
Sex: All
Age: 0 - 20
Code: NCT00345553
Recruiting
Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
for
B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative,
Location: Orange CA, Irvine CA, Duarte CA, La Jolla CA, Nampa ID,
Sponsor: National Cancer Institute (NCI)
Sex: All
Age: 18+
Code: NCT03739814
Phase 2, Recruiting
CD33-CAR T Cell Therapy for the Treatment of Recurrent or Refractory Acute Myeloid Leukemia